secwatch.observer — SEC 8-K summary
======================================

Issuer:     MESA LABORATORIES INC /CO/ (MLAB)
CIK:        0000724004
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001437749-24-019257
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mesa Labs Q4 net loss of $254.6M on $274.5M impairment; core organic revenues down 3.5%
--------------------------------------------------------------------------------

- Q4 revenue $58.9M (+6% YoY); core organic revenue declined 3.5% due to headwinds in Clinical Genomics and Biopharma.
- Full-year operating loss of $272.1M includes $274.5M non-cash impairment of goodwill and long-lived assets.
- Non-GAAP AOI excluding unusual items rose 26.3% in Q4 to $14.9M; full-year AOI +0.7% to $50.5M.
- Clinical Genomics division restructured with 17 position eliminations, expects ~$3M annual savings.
- SDC division grew 37.3% (including GKE China acquisition); BPD and CG declined organically.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/724004/000143774924019257/0001437749-24-019257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/724004/000143774924019257/mlab20240531_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-019257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer